Scholarlink

<p>Metronidazole is a front-line drug for the treatment of <i>Helicobacter pylori</i> infections. However, its mode of action and cellular targets are poorly defined, and higher dosing and combination therapies are required to overcome resistance. Here we performed activity-based protein profiling with tailored metronidazole probes and identified chaperonin HpGroEL and thiol peroxidase HpTpx as prominent targets, the latter being essential for <i>H. pylori</i> survival under oxidative stress. Alkynylated ether probes exhibited enhanced antibacterial potency compared with the parent drug in vitro, including activity against resistant strains. Biological assays, chemical proteomics and co-crystallization studies confirmed target engagement, with enhanced binding of ether derivatives to HpTpx. Refined ether analogues exhibited favourable pharmacological profiles without cytotoxicity. The in vivo activity of ether analogues using an <i>H. pylori</i> mouse model demonstrated full bacterial eradication at low dosing of 0.3 mg kg<sup>−1</sup> day<sup>−1</sup>. Our findings reveal that stress induction and simultaneous inhibition of the stress response represent a mechanism of this compound class.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metronidazole and ether derivatives target Helicobacter pylori via simultaneous stress induction and inhibition

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Michaela K. Fiedler,
  • Marianne S. I. Pandler,
  • Ruolan Gong,
  • Sonja Fuchs,
  • Katharina Rox,
  • Verena Friedrich,
  • Dietmar Pfeiffer,
  • Dharmesh Singh,
  • Till Reinhardt,
  • Cora Mibus,
  • Matthias Huber,
  • Corinna R. Hess,
  • Raquel Mejías-Luque,
  • Markus Gerhard,
  • Michael Groll,
  • Stephan A. Sieber

摘要

Metronidazole is a front-line drug for the treatment of Helicobacter pylori infections. However, its mode of action and cellular targets are poorly defined, and higher dosing and combination therapies are required to overcome resistance. Here we performed activity-based protein profiling with tailored metronidazole probes and identified chaperonin HpGroEL and thiol peroxidase HpTpx as prominent targets, the latter being essential for H. pylori survival under oxidative stress. Alkynylated ether probes exhibited enhanced antibacterial potency compared with the parent drug in vitro, including activity against resistant strains. Biological assays, chemical proteomics and co-crystallization studies confirmed target engagement, with enhanced binding of ether derivatives to HpTpx. Refined ether analogues exhibited favourable pharmacological profiles without cytotoxicity. The in vivo activity of ether analogues using an H. pylori mouse model demonstrated full bacterial eradication at low dosing of 0.3 mg kg−1 day−1. Our findings reveal that stress induction and simultaneous inhibition of the stress response represent a mechanism of this compound class.